" "
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Sygnature Discovery and Proteros Biostructures Establish Strategic Alliance

Published: Wednesday, October 23, 2013
Last Updated: Wednesday, October 23, 2013
Bookmark and Share
Under the terms of the agreement, Sygnature and Proteros will collaborate to provide integrated services to advance clients’ drug discovery projects.

This new alliance adds an integral component to Sygnature’s ‘federated’ CRO Model, which provides fully-integrated drug discovery services to the pharmaceutical industry.

Dr Torsten Neuefeind, CEO, Co-founder at Proteros said, "Sygnature has a growing reputation as a provider of premium integrated drug discovery services.  Proteros has worked with Sygnature on a number of drug discovery projects, so we already have an established working relationship.  This strategic alliance combines the complementary skills of Proteros and Sygnature Discovery.  Proteros will continue to provide X-ray protein structure analysis independently, but will also be able to contribute to fully-integrated drug discovery programmes via Sygnature’s ‘federated’ CRO model.  Working closely together on drug discovery projects, we are confident that Proteros and Sygnature can advance clients’ programmes more efficiently and effectively.”

Commenting on the strategic alliance, Dr Simon Hirst, Sygnature’s CEO said, “Proteros has specialist skills in early stage drug discovery that are highly-complementary to our own.  Proteros has an outstanding reputation for providing unique and best-in-class technologies for X-ray protein crystallography, kinetic and thermodynamic profiling and tailor-made protein production.  Sygnature and Proteros have already collaborated on a number of challenging client projects.  The close working relationship that we have established will be cemented through this strategic alliance.  With the addition of Proteros to the ‘federated’ CRO Model, it enables Sygnature to offer its customers a world class, fully-integrated drug discovery service where novel compounds can be designed, synthesised and screened in vitro at Sygnature, X-ray protein structure analysis undertaken at Proteros, metabolic liability and toxicity assessed at Cyprotex and then tested at Saretius and Pneumolabs in pharmocodynamic and disease-relevant models.  This powerful federation of alliance partners will help accelerate our clients’ drug discovery programmes towards development.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Sygnature Discovery’s Group Invests in New Start Up, Peak Proteins
Investment is part of an ongoing strategy to build and expand the Group’s extensive capabilities.
Thursday, January 28, 2016
Sygnature Discovery Strengthens Team with Three Key Appointments
Company appoints Dr Tim Schulz-Utermoehl, Dr Martin Quibell and Dr Scott Pollack.
Saturday, January 31, 2015
Controlling Gas Liquid Chemistries
Sygnature Discovery has reported results demonstrating how the Uniqsis FlowSyn™ flow reactor system allows them to perform traditionally hazardous chemistries in a controlled manner.
Monday, January 21, 2013
Scientific News
Microdroplet Reactors Mimic Living Systems
Researchers use microdroplets to study non-equilibrium reactions like those in living organisms.
NIH Researchers Identify Striking Genomic Signature for Cancer
Institute has identified striking signature shared by five types of cancer.
CRI Develops Innovative Approach for Identifying Lung Cancer
Institute has developed innovative approach for identifying processes that fuel tumor growth in lung cancer patients.
Envigo Rat Models Proven to be Susceptible to Intra-Vaginal HSV-2 Infection and Protectable
Scientific findings establish the effectiveness of new approach to investigate the protective effects of vaccine candidates and anti-viral microbodies and to study asymptomatic primary genital HSV-2 infection.
What do Banana Peels and Human Skin Have in Common?
Human skin and banana peels have something in common: they produce the same enzyme when attacked. By studying fruit, researchers have come up with an accurate method for diagnosing the stages of this form of skin cancer.
The Spice of Life
Scientists discover important genetic source of human diversity.
Cytoskeleton Crew
Findings confirm sugar's role in helping cancers survive by changing cellular architecture.
The Power of Three
Overlooked portion of cell “death receptor” critical in some cancers, autoimmune diseases.
Drug that Activates Innate Immune System Identified
Researchers from the institute have identified a drug, which is straightforward to synthesize and to couple to antigens that induce an immune response and may prove useful in the generation of vaccines.
Removing Race from Human Genetic Research
A group of scientists are urging their colleagues to take a step forward and stop using racial categories when researching and studying human genetics.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!